Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: an open-label study

被引：0
|
作者：
Paller, Amy [1 ]
Flohr, Carsten [2 ]
Eichenfield, Lawrence F. [3 ]
Irvine, Alan D. [4 ]
Pinto-Correia, Ana [5 ]
Natalie, Chitra R. [5 ]
Pierce, Evangeline [5 ]
Reifeis, Sarah [5 ]
Lima, Renata Gontijo [5 ]
Laquer, Vivian [6 ]
Weidinger, Stephan [7 ]
机构：
[1] Northwestern Univ, Evanston, IL USA
[2] Kings Coll London, St Johns Inst Dermatol, London, England
[3] Univ Calif San Diego, La Jolla, CA USA
[4] Our Ladys Childrens Hosp Crumlin, Dublin, Ireland
[5] Eli Lilly & Co, Indianapolis, IN USA
[6] First OC Dermatol, Fountain Valley, CA USA
[7] Univ Hosp Schleswig Holstein, Kiel, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P072
引用
收藏
页码：60 / 61
页数：2
相关论文
共 50 条
  • [1] Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: an open-label study
    Paller, Amy
    Flohr, Carsten
    Eichenfield, Lawrence F.
    Irvine, Alan
    Correia, Ana Pinto
    Natalie, Chitra R.
    Pierce, Evangeline
    Lima, Renata Gontijo
    Laquer, Vivian
    Weidinger, Stephan
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB84 - AB84
  • [2] Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: an open-label study
    Paller, Amy
    Flohr, Carsten
    Eichenfield, Lawrence F.
    Irvine, Alan
    Pinto-Correia, Ana
    Natalie, Chitra R.
    Pierce, Evangeline
    Reifeis, Sarah
    Lima, Renata Gontijo
    Laquer, Vivian
    Weidinger, Stephan
    Isho, Nadine
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [3] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
    Amy S. Paller
    Carsten Flohr
    Lawrence F. Eichenfield
    Alan D. Irvine
    Jamie Weisman
    Jennifer Soung
    Ana Pinto Correia
    Chitra R. Natalie
    Claudia Rodriguez Capriles
    Evangeline Pierce
    Sarah Reifeis
    Renata Gontijo Lima
    Clara Armengol Tubau
    Vivian Laquer
    Stephan Weidinger
    [J]. Dermatology and Therapy, 2023, 13 (7) : 1517 - 1534
  • [4] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
    Paller, Amy S.
    Flohr, Carsten
    Eichenfield, Lawrence F. F.
    Irvine, Alan D. D.
    Weisman, Jamie
    Soung, Jennifer
    Correia, Ana Pinto
    Natalie, Chitra R. R.
    Capriles, Claudia Rodriguez
    Pierce, Evangeline
    Reifeis, Sarah
    Lima, Renata Gontijo
    Tubau, Clara Armengol
    Laquer, Vivian
    Weidinger, Stephan
    [J]. DERMATOLOGY AND THERAPY, 2023, 13 (07) : 1517 - 1534
  • [5] Long-term safety and efficacy of open-label dupilumab in patients with moderate-to-severe atopic dermatitis
    Deleuran, M.
    Thaci, D.
    Beck, L.
    Forman, S.
    Soong, W.
    Hussain, I.
    Bissonnette, R.
    Bouaziz, J.
    Gelfand, J.
    Lawrence, S.
    Chen, Z.
    Akinlade, B.
    Gadkari, A.
    Eckert, L.
    Graham, N.
    Ardeleanu, M.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 34 - 34
  • [6] Long-Term Safety and Efficacy of Open-Label Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
    Deleuran, Mette
    Thaci, Diamant
    Beck, Lisa A.
    Forman, Seth
    Soong, Weily
    Hussain, Iftikhar
    Bissonnette, Robert
    Bouaziz, Jean-David
    Gelfand, Joel
    Sher, Lawrence
    Chen, Zhen
    Akinlade, Bolanle
    Gadkari, Abhijit
    Eckert, Laurent
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (02) : AB381 - AB381
  • [7] Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis
    Guttman-Yassky, Emma
    Weidinger, Stephan
    Simpson, Eric
    Gooderham, Melinda
    Irvine, Alan
    Spelman, Lynda
    Silverberg, Jonathan
    Elmaraghy, Hany
    DeLuca-Carter, Louise
    Piruzeli, Maria Lucia Buziqui
    Hu, Chaoran
    Yang, Fan Emily
    Pierce, Evangeline
    Bardolet, Laia
    Thaci, Diamant
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II3 - II4
  • [8] Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
    Smith, Brandon I.
    Engel, Priya
    Wu, Jashin
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (24): : 2299 - 2300
  • [9] Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
    Cork, M. J.
    Eichenfield, L. F.
    Blauvelt, A.
    Rosmarin, D.
    Hussain, I.
    Davis, J. D.
    Li, M.
    Zhang, Q.
    Gadkari, A.
    Eckert, L.
    Kamal, M. A.
    Bansal, A.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S104 - S104
  • [10] Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
    Diana Bernardo
    Thomas Bieber
    Tiago Torres
    [J]. American Journal of Clinical Dermatology, 2023, 24 : 753 - 764
12345